Biohaven Pharmaceutical files to go public

New Haven, Connecticut-based Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company targeting neurological diseases, has filed for an $100 million IPO, according to an SEC filing. Biohaven has applied to list the stock on the New York Stock Exchange under the ticker symbol “BHVN.” Morgan Stanley, Piper Jaffray and Barclays are the lead underwriters. Biohaven’s shareholders include Portage Biotech Inc, Vivo Capital and RA Capital.